Fig. 1

Defined approach data interpretation procedures. Potency categories are based on the GHS: 1A: strong sensitizer, 1B: weak sensitizer; NC: not classified (non-sensitizer). 1* indicates a conclusive sensitizer hazard prediction and an inconclusive potency prediction. a The KE 3/1 STS DA predicts skin sensitization hazard and potency by evaluating results from the human cell line activation test (h-CLAT) and direct peptide reactivity assay (DPRA). b The 2o3 DA predicts skin sensitization hazard by evaluating results from the DPRA, h-CLAT, and KeratinoSens. c The ITS DA predicts skin sensitization hazard and potency by scoring results from the DPRA, h-CLAT, and in silico predictions from Derek Nexus or the OECD QSAR Toolbox. The minimum induction threshold (MIT) is a quantitative endpoint from the h-CLAT. %-Cysteine (Cys) and %-Lysine (Lys) depletion are quantitative endpoints from the DPRA.